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Abstract
Buruli ulcer (BU), caused by Mycobacterium ulcerans is a chronic necrotizing skin disease. It usually starts with a
subcutaneous nodule or plaque containing large clusters of extracellular acid-fast bacilli. Surrounding tissue is destroyed by
the cytotoxic macrolide toxin mycolactone produced by microcolonies of M. ulcerans. Skin covering the destroyed
subcutaneous fat and soft tissue may eventually break down leading to the formation of large ulcers that progress, if
untreated, over months and years. Here we have analyzed the bacterial flora of BU lesions of three different groups of
patients before, during and after daily treatment with streptomycin and rifampicin for eight weeks (SR8) and determined
drug resistance of the bacteria isolated from the lesions. Before SR8 treatment, more than 60% of the examined BU lesions
were infected with other bacteria, with Staphylococcus aureus and Pseudomonas aeruginosa being the most prominent ones.
During treatment, 65% of all lesions were still infected, mainly with P. aeruginosa. After completion of SR8 treatment, still
more than 75% of lesions clinically suspected to be infected were microbiologically confirmed as infected, mainly with P.
aeruginosa or Proteus miriabilis. Drug susceptibility tests revealed especially for S. aureus a high frequency of resistance to
the first line drugs used in Ghana. Our results show that secondary infection of BU lesions is common. This could lead to
delayed healing and should therefore be further investigated.
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Introduction
Buruli ulcer (BU) caused by Mycobacterium ulcerans is a necrotizing
skin disease that affects mainly impoverished communities in
Western and Central Africa. It is the third most common
mycobacterial disease of humans after tuberculosis and leprosy.
BU lesions are characterized by extensive necrosis and minimal
pain and inflammation [1,2]. The pathogenesis of the disease is
believed to be initiated by the inoculation of M. ulcerans into the
subcutaneous layer of the skin, which may be facilitated by trauma
or an insect vector. Most BU lesions are found at the extremities
and contain extracellular clusters of acid-fast bacilli (AFB) in the
subcutaneous fat tissue. The incubation period seems to be highly
variable, and has been estimated to range from two weeks to three
years, with an average of two to three months [3]. The disease
begins typically as a painless nodule under the skin and gradually
enlarges and erodes through the skin surface, leaving a well-
demarcated ulcer with a necrotic slough in the base and widely
undermined edges [3,4].
Traditionally, the mainstay treatment of BU was surgical
removal of infected tissues followed by skin grafting [1]. This led to
long hospital stays with the accompanied social problems of losses
of school time by children and a large economical burden directly
and indirectly to the affected families. Since 2006, after a pilot
study in Ghana, the first line treatment of BU is SR8 (eight weeks
of streptomycin daily injections and oral therapy with rifampicin)
[5–7]. This has reduced surgery to an adjunct procedure in BU
management. The general perception is that this treatment
modality will reduce the length of stay in health facilities, since it
removes the fear of surgery and encourages early reporting to the
formal health sector for treatment. SR8 makes a decentralization
of treatment possible, since staff of peripheral health facilities can
administer streptomycin injections.
The pathogenesis of BU is mediated mainly by a polyketide
derived macrolide toxin, named mycolactone, with potent tissue
necrotizing [8] and immunosuppressive activities [9,10]. Myco-
lactone produced by clusters of M. ulcerans leads to the destruction
of the surrounding soft skin tissue and to the formation of
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devitalized, avascular tissue and ‘necrotic slough’ at the wound
bed, which is very characteristic of BU [11]. The necrotic tissue
could provide an ideal medium for bacterial growth and may
disturb and delay wound healing. While there is a popular belief
that secondary infections of BU lesions are rare, because
mycolactone has antimicrobial activities, there is no published
evidence base for this.
It is controversial, whether bacteria present in wounds
contribute to delays in wound healing, because wounds generally
harbor transient microorganisms (contamination) [12]. The
surfaces of wounds have microbial populations at each stage of
healing and some of the bacteria may be involved in mutually
beneficial relationships with the host preventing more virulent
organism from infecting deeper tissues. Such beneficial organisms
include coagulase negative Staphylococcus and Corynebaceria species
[12–14]. These contaminating organisms are derived from the
normal flora of the surrounding skin, mucous membranes or from
external environmental sources. Usually the immune defense
mechanisms of the host can contain these contaminants with no
harm and negative consequence to wound healing. However,
some of the contaminating organisms can also go on to colonize,
massively multiply and delay wound healing. Only when a critical
concentration of these microorganisms is reached, signs of
infection including erythema, pain, increase in temperature, odor
and discoloration of granulation tissue are observed. Therefore
assessment of wound infection has to be based both on the density
of microorganisms as well as on the presence of specific pathogenic
species [15,16]. Staphylococcus aureus, Pseudomonas aeruginosa, and
beta-hemolytic streptococci are regarded as primary indicators for
a delayed healing and infection in both acute and chronic wounds.
Bacterial loads exceeding 106 colony forming units (CFU)/g of
tissue or tissue fluid, accumulations of pus cells and presence of
specific pathogenic organism are being used as indicators for
wound infection in contrast to wound contamination [16–19].
Factors predisposing a wound to infection include the non-
observance of principles of good hygienic procedures during
dressing and the presence of necrotic tissue or slough within the
wound margin [13], which is commonly found in BU lesions. The
extent of secondary infections in BU and their contribution to
frequently observed delays in healing has not been studied so far.
Here we have analyzed BU lesions before, during and after
antimicrobial treatment for the presence of secondary infection.
Materials and Methods
Study participants and sample collection
The participants involved in the study were recruited from the
Amasaman District Hospital and the Obom Health Centre in the
Ga-West and Ga South Municipality, respectively. The partici-
pants were all laboratory confirmed BU cases and the analyzed
samples fall into three main categories: 1) samples from 53 BU
patients recruited consecutively before treatment; 2) samples from
20 BU patients recruited consecutively between four and six weeks
after start of SR8 and 3) samples from 31 BU patients whose
lesions were clinically suspected of secondary infection after SR8
treatment. Some of the participants overlapped in some of the
categories: 71 of the participants were sampled once for analysis,
12 twice and 3 thrice within the study period, thus in total 104
individual samples, 84 swabs and 20 tissue samples, from 86
participants were analyzed. The swabs were obtained from 52
cases before treatment, 20 cases during and 12 cases after
treatment and analyzed microbiologically (Table S1). The tissue
samples for histopathological analysis were obtained from one case
before treatment and 20 cases after treatment. Except for one
sample taken after treatment, all tissue samples were also analyzed
microbiologically (Table S1).
A detailed questionnaire was used to obtain standard demo-
graphic data, document the clinical presentation of lesions and
other lesion characteristics. Altogether the study involved 86
participants comprising 32 (37%) females and 54 (63%) males.
The females’ age ranged between two and 72 years and the males
were between four months and 82 years. Median age for both
groups was 33 years. Seventy-seven of the cases had lesions located
on the limbs, three in the head and neck region, and one each
located on the buttocks, armpit and back respectively; the lesion
location of three participants was not documented.
Only 2/86 patients were pre-ulcerative. These lesions, one
nodule and one plaque, were sampled later during surgery. The
remaining 84 patients had ulcers; 78 of them had only ulcers, one
had an ulcer and a nodule, three had ulcers with edema, and two
had ulcers with osteomyelitis. Based on the judgment of the
responsible clinician, surgical debridement was performed for 1
patient prior to treatment and for 20 patients after completion of
SR8. Biopsy samples were collected in each instance for
histopathological analysis (Figure 1).
Laboratory confirmation of BU disease was done by IS2404
PCR and Ziehl-Neelsen microscopy as previously described
[20,21]. Three swab samples were collected from clinically
suspected ulcerative cases before treatment; one for IS2404-PCR
based confirmation of BU, one for preparation of a direct smear
for microscopic examination for the detection of bacteria and
neutrophils after Gram staining (Figure S1), and the third was
inserted into a sterile tube containing 3 ml of PBS for enumeration
of the bacterial burden and the isolation of specific bacterial
species. All swab specimens were collected from the undermined
edges of lesions by first moistening the swab with sterile PBS using
the Levine method of collecting swab specimen [22]. This has
been found to be the best method for taking swabs as it is more
reflective of tissue bio-burden as compared to other methods [23].
After cleaning the wound surface with normal saline, a swab was
rotated over a 1 cm2 area with sufficient pressure to collect the
fluid from within the wound tissue.
Author Summary
Buruli ulcer (BU) can lead to large ulcerative lesions due to
extensive skin loss caused by the necrotizing effect of the
main virulence factor mycolactone. For a long time the
general perception was that BU lesions are not infected by
other bacteria because of a postulated antimicrobial effect
of the macrolide toxin, mycolactone. In this study, we
analyzed laboratory confirmed BU lesions before, during,
and after streptomycin/rifampicin treatment. Contrary to
popular belief, our findings show that BU lesions are
frequently co-colonized with other potential bacterial
pathogens before, during, and after antibiotic treatment.
For example, 75% of cases that were clinically indicative of
being infected after treatment were microbiologically
confirmed as infected. Most microbiologically infected
cases were also confirmed by histopathological analysis.
The most prominent bacterial species isolated included
Pseudomonas aeruginosa, S. aureus, and P. mirabilis. When
we tested the isolates against first line drugs used in
Ghana, the isolates were found to be resistant to most of
these drugs. This study indicates that wound care practices
need to be improved and that wound infection may be a
common cause of wound healing delay in BU.
Bacterial Infection of Buruli Ulcer Lesions
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From cases that were sampled during treatment and those that
were clinically suspected of having a bacterial infection after
completion of SR8, three swab specimens were collected before
surgery, and treated as above, except for the procedures for the
laboratory confirmation of BU disease by PCR, since all cases had
been previously confirmed as BU within the framework of a bigger
study. From SR8 treated patients that underwent surgical
management, tissue sample were analyzed if there was clinical
suspicion of a secondary bacterial infection. While one sample was
aseptically transferred into a clean sterile tube for enumeration of
the bacterial load and species identification, a second sample was
directly transferred into 10% neutral buffered formalin for
histopathological analysis.
The samples for bacteriological analysis were placed in an ice
chest with ice packs to prevent bacterial multiplication and
transported to the Bacteriology Department of the Noguchi
Memorial Institute for Medical Research (NMIMR) for analysis,
Tissue samples for were shipped to the Swiss Tropical and Public
Health Institute for histopathological analysis.
Ethics statement
Ethical clearance was obtained from the institutional review
board of the Noguchi Memorial Institute for Medical Research
(Federal-wide Assurance number FWA00001824). The procedures
for sampling in this study were essentially the same as those used in
routine management of BU in Ghana. However, written informed
consent was collected from all participants before study inclusion.
In the case of children below sixteen years, written informed
consent was collected from their parents or guardians. Patients
were assured of the confidentiality of all information collected
during the study.
Enumeration of the bacterial load and isolation of
bacteria
When swab samples reached the microbiology laboratory, the
volume of PBS was topped up to 5 ml and both the swab and the
PBS were transferred into a sterile glass tissue culture tube
containing glass beads. The tubes were vortexed for about two
minutes to dislodge any particles that were sticking to the swabs.
Using the resulting stock suspension, serial dilutions from 1022 to
1026 were prepared.
Hundred microlitres of serial dilutions of the swab or tissue
suspensions were transferred into sterile Petri dishes and inocu-
lated by the pour plate method using Plate Count Agar for total
aerobic counts. The agar was left on the lab bench to set after
which it was incubated at 37uC for 18–24 hours. The remaining
1021 dilution of the suspension was centrifuged at 8,000 g for
25 minutes and after decanting, the pellet was inoculated onto
Figure 1. Histopathological analysis of tissue excised before start of SR8 treatment. Histological sections were stained with Ziehl-Neelsen
(acid fast bacteria) and methylene blue (DNA, secondary infection). A: Overview over excised tissue specimen revealing infection at the lower end of
the specimen (box), as well as BU characteristic histopathological features, including fat cell ghosts, necrosis and epidermal hyperplasia. B/C: higher
magnification revealing the presence of cocci. D: clinical presentation of the lesion on the belly.
doi:10.1371/journal.pntd.0002191.g001
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MacConkey, Blood and Chocolate agar and incubated under
aerobic conditions. The aerobic agar plates were examined after
24 hours and growing colonies were subcultured on Blood and
MacConkey agar plates to obtain pure cultures.
After incubation, the plates were examined using a colony
counting chamber (Gallenkamp, UK) and those with colony
counts between 30 and 300 were selected for computing CFU/ml
or CFU/g, respectively, by multiplying the counts by the dilution
factors. The lesion from which the sample was taken was classified
as clean, contaminated or infected as indicated in the data analysis
section.
For tissue specimen, one gram of sample was weighed in a
sterile plastic stomacher bag. Nine milliliters of PBS were added,
samples were macerated in a stomacher and the resulting
suspension was transferred into a sterile test-tube. Using this stock
suspension, serial dilutions were prepared and plated out.
Species identification of bacterial isolates
Distinct bacterial colonies from the Blood and MacConkey agar
plates were purified on Nutrient agar plates for identification.
Bacterial isolates were Gram stained [24] and identified by
biochemical tests as well as by molecular methods. Gram negative
rod isolates were characterized by cytochrome oxidase analysis,
and with Analytical Profile Index (API 20E) strips (bio-Me´rieux
SA, Marcy-l’E’toile, France) according to the manufacturer’s
instructions. Gram positive cocci were analyzed after Gram
staining using the catalase test to differentiate between Staphylococ-
cus spp. and Streptococcus spp. In order to further discriminate the
catalase positive Gram positive cocci and especially to identify
Staphylococcus spp., the Staphylase kit Prolex Latex Agglutination
System (Pro-Lab Diagnostics) was used. Gram positive bacteria
were further characterized using the Hain Lifescience Genotype
Product series for Gram positive bacteria Genotype BC Gram
positive version 3.0 and Genotype staphylococcus version 2 test
kits (Hain Lifescience, Germany). Where species identification
failed with the analytical profile index and the other biochemical
assays, identification was achieved by MALDI-TOF mass
spectrometry [25].
Drug susceptibility testing
Susceptibility of isolates to specific drugs was tested using the
Kirby-Bauer disc diffusion method on Mueller Hinton agar [26].
Sensitivity was tested against antibiotics such as Cotrimoxazole,
Ampicillin, Tetracycline, Ciprofloxacin, Amikacin, Gentamicin,
Penicillin, Erythromycin, Cefuroxime, Cefixime, Ceftriaxone,
Chloramphenicol and Flucloxacillin. In addition Gram positive
cocci were tested against methicillin and vancomycin. The results
of isolation and drug sensitivity tests were provided to the treating
clinician at the collaborating health facility. Since the locally
available disc systems varied in coverage, some antibiotics were
only tested with a subset of isolates. One limitation of this study is
that we did not test for susceptibility against streptomycin and
rifampicin.
Histopathology
Histopathological analysis was done for all SR8 treated patients
needing surgical management and presenting with a lesion
clinically suspicious for secondary infection. Surgically excised
tissue samples were immediately fixed after excision in 10%
neutral-buffered formalin for 24 h at room temperature to
maintain tissue structures. Afterwards samples were directly
transferred to 70% ethanol for storage and transport. Tissue
specimens were subsequently dehydrated, embedded into paraffin,
and cut into 5 mm sections. After deparaffinization and rehydra-
tion, sections were stained with Ziehl-Neelsen/Methyleneblue
(ZN) according to WHO standard protocols [3]. In this staining
AFB appear pink and other bacteria are stained blue. Tissue
sections were analyzed with a Leica DM2500 Microscope and
pictures were either taken with a Leica DFC 420C camera or with
an Aperio ScanScope XT.
Analysis of recycled bandages
Recycled bandages from fifteen confirmed BU cases were
collected conveniently before wound dressing for microbiological
analysis. Ten grams bandage was weighed, added to 90 ml of
sterile PBS and macerated with a laboratory blender to give a
1021 dilution. Using this suspension, serial dilutions from 1022 to
1026 were prepared. Hundred microlitres of these serially diluted
suspensions were transferred into sterile Petri dishes and inocu-
lated by the pour plate method using Plate Count Agar for total
aerobic counts. Bacterial enumerations were performed as
described above. In addition the left over suspension was
centrifuged at 3,000 g for 20 mins and the resulting pellet was
plated for bacterial isolation.
Data analysis
The values obtained from plate counts were computed into
CFU/ml for wound exudates (swabs) or CFU/g for tissue sample.
The antibiogram of each isolate was interpreted according to the
manufacturer’s specification as resistant, intermediate or suscep-
tible. The percentages of cases in each category were then
computed.
Classification of wounds
Lesions were classified microbiologically as clean if no bacteria
were isolated, as contaminated if bacterial counts were
,106 CFU/g or ml and as infected if counts were .106 CFU/g
or ml of specimen.
Lesions were clinically classified as infected based on the
following criteria: 1. friable, bleeding granulation tissue despite
appropriate care and management; 2. purulent discharge (yellow
or green) from wound or drain placed in wound; 3. pain or
tenderness, localized swelling (edema), or redness/heat; 4. tissue
necrosis; 5. skin grafting failure; abnormal odor coming from the
wound site; delayed healing not previously anticipated. Twenty-
four of the patients clinically classified as infected were in-patients
and seven were out-patients, who were reporting twice a week for
wound dressing. During wound dressing, the wounds were cleaned
with normal saline to wash away debris. Wounds that appeared
necrotic or had an offensive odor were cleaned again with vinegar
and dressed with povidine iodine.
Results
Bacterial infection of lesions from PCR-confirmed BU
patients before and during SR8 treatment
Swab samples of 52 consecutively recruited IS2404 PCR
confirmed BU cases with ulcerative lesions were sampled before
the commencement of SR8 treatment. Samples from three
participants (5.7%) did not yield any aerobic growth on plate
count agar (Table 1). Seventeen (32.1%) of the lesions with total
CFU counts of 1.76103 to 9.06105 CFU/ml (average
3.26105 CFU/ml) were microbiologically classified as contami-
nated. Microbiologically Infected lesions were observed in 33/52
patients (63.5%); aerobic counts from this group ranged between
1.06106 to 3.56109 CFU/ml with an average value of
1.16109 CFU/ml. The most frequently identified bacterial species
from the infected lesions prior to start of treatment (Table 1) were
Bacterial Infection of Buruli Ulcer Lesions
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S. aureus (n = 9; 21.4%), P. aeruginosa (n = 7; 16.7%) and P. mirabilis
(n = 6; 14.3%).
The responsible clinician decided to perform wound debride-
ment of one of the lesions prior to SR8 initiation, since it showed
clinical signs of a strong secondary infection (Figure 1D). A biopsy
specimen was taken and the histopathological analysis of the tissue
sample (Figure 1A–C) revealed, typical hallmarks of BU, such as
fat cell ghosts, tissue necrosis and epidermal hyperplasia
(Figure 1A). In addition, clusters of cocci were observed in the
subcutaneous tissue between the fat cells (Figure 1A box, B, C).
This area probably represents the tissue base of the undermined
edges. These findings correlated well with the microbiological
analysis, since S. aureus was isolated in large numbers from the
lesion (1.26109 CFU/g).
Twenty laboratory-confirmed BU cases were consecutively
sampled between four and six weeks after start of SR8
treatment and analyzed for infection of the lesions. Of these
lesions, 7/20 (35.0%) and 13/20 (65.0%) were microbiologi-
cally classified as contaminated or infected, respectively; clean
wounds were not observed (Table 1). The aerobic bacterial
load ranged between 1.56106 and 3.56109 CFU/ml, with an
average value of 5.66108 CFU/ml for the microbiologically
infected lesions. The contaminated lesions had counts between
5.26103 and 7.36105 CFU/ml (average 3.36105 CFU/ml).
Also here P. aeruginosa (n = 6; 35.3%) and P. mirabilis (n = 2;
11.8%), but not S. aureus (n = 0), were the most frequently
identified bacterial species isolated from the infected lesions
(Table 1).
Table 1. Spectrum of bacterial species isolated from BU lesions before, during or after SR8 treatment.
Time of sampling Clean wounds Contaminated wounds Infected wounds
Spectrum of bacteria isolates from infected
cases n (%)
Before SR8 Treatment (n = 53) 3 (6%) 17 (32%) 33 (62%) 9 (22%) Staphylococcus aureus
7 (17%) Pseudomonas aeruginosa
6 (15%) Proteus mirabilis
3 (7%) Coagulase negative Staph.
3 (7%) Chryseomonas luteola
2 (5%) Enterobacter cloacae
2 (5%) Klebsiella pneumonia
2 (5%) Escherichia coli
1 (2%) Streptococcus dysgalactia
1 (2%) Providencia stuartii
1 (2%) Staphylococcus haemolyticus
1 (2%) Morganella morganii
1 (2%) Streptococcus agalactia
1 (2%) Staphylococcus warneri
1 (2%) Proteus vulgaris
During SR8 Treatment (n = 20) 0 (0%) 7 (35%) 13 (65%) 6 (38%) Pseudomonas aeruginosa
2 (13%) Proteus mirabilis
1 (6%) Staphylococcus warneri
1 (6%) Coagulase negative Staph.
1 (6%) Enterobacter cloacae
1 (6%) Providencia stuartii
1 (6%) Staphylococcus haemolyticus
1 (6%) Enterococcus gallinum
1 (6%) Flavibacterium oryzihabitans
1 (6%) Chryseomonas luteola
After SR8 Treatment (n = 31;
clinically diagnosed for
secondary infection)
0 (0%) 7 (23%) 24 (77%) 8 (32%) Pseudomonas aeruginosa
5 (20%) Proteus mirabilis
3 (12%) Staphylococcus aureus
2 (8%) Escherichia coli
2 (8%) Providencia stuartii
2 (8%) Klebsiella pneumoniae
1 (4%) Coagulase negative Staph.
1 (4%) Alcaligenes faecalis
1 (4%) Acinetobacter sp
doi:10.1371/journal.pntd.0002191.t001
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Bacterial infection of BU lesions with clinical signs of
infection after completion of SR8 treatment
Thirty-one BU lesions with clinical signs of secondary bacterial
infection after completion of SR8 treatment were sampled for
laboratory investigation. Clinical signs indicative for secondary
infection were documented for 28 of them and included: localized
pain (28/28), viscous/purulent discharge (28/28), edema (5/28)
and localized heat (4/28). In addition, delayed healing not
previously anticipated (17/28), offensive odor (15/28) and
discoloration of tissues both within and at the wound margins
(3/28) were regarded as signs of secondary infection (Table 2). The
time at which infection was detected ranged from a few weeks to
fifteen months after completion of SR8.
Seven (22.6%) of the 31 lesions clinically suspected to be
infected were not confirmed microbiologically by aerobic bacterial
count analysis, as the total plate count ranged only between
1.36103 and 8.96105 CFU/ml (average 2.76105 CFU/ml). The
remaining twenty-four (77.4%) lesions that were microbiologically
confirmed as infected had plate counts ranging between 1.26106
and 3.56109 CFU/ml (average value of 1.26109). P. aeruginosa
(n = 8; 32%), P. mirabilis (n = 5; 20%) and S. aureus (n = 3; 12%)
dominated among the isolates.
The bacterial load observed in cases analyzed within four weeks
post SR8 ranged between 1.36103 and 4.06109 CFU/ml; that
between five and 12 weeks was between 9.36104 and
1.26109 CFU/ml; and that between 9 and 15 months post SR8
ranged between 2.76106 and 1.86109 CFU/ml. Nineteen tissue
samples and 12 swab samples were analyzed (Table S1) and the
bacterial load ranged between 1.36103 and 4.06109 CFU/ml for
tissues and between 5.26107 and 2.16109 for swabs.
Tissue samples from 20/31 of the microbiologically analyzed
lesions showing clinical signs of secondary infection after
completion of SR8 were also analyzed by histopathology, since
the responsible clinicians decided to perform a wound debride-
ment. Microbiological analysis had categorized 16 of these lesions
as infected and four as contaminated. None of the microbiolog-
ically contaminated wounds presented in the histopathological
analysis with a detectable secondary infection. In contrast 12/16
(75%) of the lesions classified microbiologically as infected
presented with an infection either with cocci, rods or both
(Table 2). Infection was mainly observed in the stratum corneum
(6/12; 50%) or on the open ulcer surface (3/12; 25%) and only
rarely (3/12; 25%) deeper inside the excised tissue (Table 2).
Histopathological analysis of specimen from patient 9 (Figure 2 A–
D) revealed a layer of densely packed rods at the open ulcer
surface visible already at low magnification as an intensely blue
stained band (Figure 2B) At higher magnification, clusters of rod
shaped bacteria were observed (Figure 2 C,D). Microbiological
analysis confirmed the presence of P. aeruginosa. Tissue excised
from patient 16 (Figure 2E–H) showed a double infection: cocci
being present inside the stratum corneum (data not shown) as well
as an extensive infection of the dermal and subcutaneous tissue
with rods (Figure F–H). Microbiological analysis isolated S. aureus
as well as Gram-negative rods. In most of our analysis,
histopathological and microbiological results showed a good
correlation for most of the patients (Table 2).
Drug susceptibility pattern of bacterial isolates
Using the disc diffusion assay, a total of 98 Gram-negative rods
and Gram-positive cocci obtained from BU wounds were tested
for resistance against antibiotics commonly used in Ghana. None
of the isolates tested was sensitive to all drugs included in the
analysis (Table 3). Five Gram-negative rods were resistant to all
tested drugs. More than 70% of the 18 S. aureus isolates obtained
from infected (n= 12) or contaminated (n= 6) lesions were
resistant to flucoxacillin, ampicillin and penicillin. In contrast,
15/18 (83%) were susceptible to gentamicin. The prevalence of S
aureus isolates resistant to methicillin (MRSA) and vancomycin
(VRSA) was 33% and 17%, respectively.
Likewise most of the P. aeruginosa strains were resistant to most of
the tested drugs. However, most isolates (18/22; 82%) were
susceptible to gentamicin. Results for the other Gram-negative and
-positive bacteria are provided in Table 3.
Microbiological analysis of recycled bandages
When monitoring wound management procedures, it was
realized that patients and care-givers were instructed by health
workers to wash and recycle dressing bandages. We therefore
conveniently sampled dressings that have been used and washed
for the next dressing. Seventeen bandages from fifteen BU cases
were analyzed and as shown in Table 4, all of them had some
bacterial contamination with total aerobic plate counts ranging
between 2.26103 and 3.26108 CFU/g with an average count of
2.86107 and a median value of 1.26105 CFU/g. While bacterial
species identified included commensals such as staphylase negative
Staphylococcus spp., also potential pathogens including S. aureus, P.
aeruginosa, Flavibacterium oryzihabitans, Enterobacter agglomerans and
Enterobacter cloacae were isolated. The drug susceptibility patterns of
isolates are indicated in Table 4. Similar isolates were also isolated
from patients’ wounds.
Discussion
Mycolactone, the cytotoxic macrolide toxin of M. ulcerans plays a
key role in the pathology of BU. It causes apoptosis of mammalian
cells [8,27] and has immunomodulatory activity [28,29]. Since a
number of macrolides have antibiotic activity against a broad
spectrum of bacteria, including streptococci, pneumococci, staph-
ylococci, enterococci, mycoplasma, mycobacteria, rickettsia, and
chlamydia [30], it has been speculated that mycolactone secreted
by M. ulcerans during active disease prevents secondary bacterial
infections of BU lesions. The goal of this study was to find out
whether ulcerative BU lesions are indeed rarely colonized or
infected by other bacterial species. To address this, BU wounds
were characterized before SR8 treatment by both direct smear
microscopic analysis for the presence of bacteria and neutrophils
[20] and by pour plate determination of aerobic CFU counts.
More than 60% of the lesions tested before treatment had bacterial
counts $106 CFU/ml and direct smear examination frequently
showed large numbers of bacteria and neutrophils (Figure S1). A
broad spectrum of bacterial species was isolated from the lesions
with S. aureus, P. aeruginosa and P. mirabilis being the most frequently
found species. This suggests that M. ulcerans infection and
mycolactone secretion does not prevent secondary bacterial
infections.
Chronic wounds often have a bacterial burden that is massively
exceeding levels used to define lower limits for the definition of
infection in acute surgical wounds (i. e. 106 CFU/g of tissue).
However, many chronic wounds go on to closure despite levels of
infecting microorganisms $108 CFU/g of tissue, with infection by
Group B streptococci being one exception to this rule [12,13,16].
Because of the intrinsic differences in the way acute and chronic
wounds respond to the burden of microorganism, emphasis is
currently being placed on holistic assessments, with clinical signs
and symptoms playing key roles in the diagnosis of chronic wound
infection. Clinical signs usually employed for diagnosis include
erythema, edema, heat, purulent exudates with concurrent
inflammation, pain, delayed healing, discoloration of granulation
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tissue, friable granulation tissue, pocketing at the base of the
wound, foul odor, and wound breakdown [13,14,17]. In particular
increasing pain and wound breakdown have been shown to be
good predictors of infection in chronic wounds. In this study we
combined clinical, histopathological, qualitative and quantitative
microbiological methods to analyze BU lesions for the presence of
infections after completion of SR8 treatment. Lesions from 28
patients showing clinical signs of infection were included in this
analysis. 75% of these lesions yielded CFU counts .106 CFU/ml
(average value of 1.26109) and frequently species with pathogenic
potential, such as S. aureus, P. aeruginosa, S. haemolyticus, E. cloacae
and K. pneumonia were isolated. Pain and yellow discharge turned
out to be highly predictive clinical indicators for infection. For the
patients that had clinical signs of infection after SR8, culture and
drug susceptibility testing results were submitted to the treating
officer. However documentation of the treatment and subsequent
follow-up of patients was beyond the scope of this study.
A study analyzing the microbial flora of healing and non-
healing decubitus ulcers [31] found S. aureus, Streptococcus spp., E.
coli, Klebsiella spp., Proteus spp. and P. aeruginosa as the main
organisms that caused infection of the ulcers. Chronic venous
ulcers have been found to be infected with S. aureus, P. aeruginosa,
Coagulase-negative staphylococci, Proteus spp. and anaerobic
bacteria [32]. Thus most of the organisms isolated in this study
from BU lesions have also been found associated with infection of
other types of wounds. Similar to what has been reported in other
studies [33], lesions were in many cases infected with more than
one bacterial species (Table 2). Our data on the microflora of
lesions upon admission indicate that BU lesions may be
contaminated from the communities as a result of improper
wound care practices by the patients in their quest to treat the
infection either on their own or with the help of traditional healers
or herbalists. There is major concern about subsequent acquisition
of antibiotic resistant organisms from the hospital settings. After
the present pilot study demonstrating colonization and infection
during and after SR8 treatment, we plan to perform longitudinal
studies with patient cohorts to study the influence of BU wound
management practices on secondary bacterial infections.
The method used for collecting wound specimens can influence
the data obtained from microbiological culturing. Currently,
collection of a biopsy specimen is the gold standard for
determining the presence and identity of microorganisms within
the wound bed tissue [12,16,34–37]. However, there are
limitations as to which healthcare providers can collect biopsies,
the availability of laboratories offering microbiological culture
testing on biopsies, the expenses involved with the performance of
these tests, and the potential for further tissue damage and delay of
wound healing when biopsies are taken. In the present study we
employed swabbing [22,36] as the main sampling procedure and
performed histopathological studies with tissue specimen only
Figure 2. Histopathological analysis of tissue from two patients excised weeks after SR8 treatment respectively. Histological sections
were stained with Ziehl-Neelsen (acid fast bacteria) and methylene blue (DNA, secondary infection). A: clinical presentation of patient 9 presenting
with a large lesion on the right foot. B: overview over excised tissue specimen (open ulcer surface) revealing the presence of an infection (blue band,
box). C/D: higher magnification confirming the presence of densely packed rods. E: clinical presentation of patient 16 presenting with a large lesion
covering the left leg. F: overview over excised tissue specimen revealing an epidermal hyperplasia as well as a strong edema. G/H: secondary infection
with rods of the dermal and subcutaneous tissue.
doi:10.1371/journal.pntd.0002191.g002
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from 20 cases that underwent surgical intervention. The
histopathological analysis detected bacterial populations in 75%
(12/16) of the analyzed lesions classified as infected and in none
(0/4) of the lesions classified as contaminated. This strong
correlation between results obtained with tissue and swab samples
confirms results of previous studies [23] indicating that microbi-
ological swabbing is a good sampling procedure for the
determination of infection of wounds. Histopathological analysis
detected infecting bacteria populations only rarely deeper inside
the excised tissue and mainly in the stratum corneum or on the
open ulcer surface, where bacteria are accessible for the swabs.
Contamination of BU lesions prior to SR8 treatment may be a
result of wound care practices by the patients. Also during SR8
treatment a range of bacterial species, with Gram-negative rods
dominating, were isolated from the lesions. This indicates that
SR8 does not necessarily eliminate contamination or secondary
infection of lesions. Bacterial species, such as P. aeruginosa, K.
pneumoniae and S. aureus isolated from infected lesions after
completion of SR8 treatment, may however also have been
acquired from the hospital setting. A detailed characterization of
isolates is required to address this important issue further. Both
mono and multiple antibiotic resistant strains were isolated with
high frequency from the BU lesions. For example all the tested S.
aureus strains were resistant to penicillin, 22% were methicillin
resistant and 17% vancomycin resistant. Dependent on the setting,
both lower (Nigeria, [38]) or higher (South-Africa, [39]) frequen-
cies have been reported in Africa. Most worrying in this context is
the high (83%) level of resistance of S. aureus isolates to
flucloxacillin, which is in Ghana the main antibiotic in use for
treating skin infections such as boils and cellulitis. In addition, we
Table 3. Antibiotic susceptibility pattern of different bacterial species isolated from BU wounds.
Pathogen Drug Tested Number Tested Susceptible, n(%) Int. Resistant, n(%) Resistant n(%)
Pseudomonas aeruginosa Gentamicin 22 18(81.9) 1(4.5) 3(13.6)
Ceftriaxone 13 3(23.1) 7(53.8) 3(23.1)
Cefotaxime 20 1(5.0) 1(5.0) 18(90)
Ampicillin 22 0(0) 0(0) 22(100)
Tetracycline 22 3(13.6) 1(4.5) 18(81.9)
Cotrimoxazole 22 3(13.6) 2(0) 17(77.3)
Cefuroxime 22 0(0) 0(0) 22(100)
Chloramphenicol 21 2(9.5) 2(9.5) 17(81)
Staphylococcus aureus Tetracycline 18 12(66.7) 0(0) 6(33.3)
Cotrimoxazole 18 16(88.9) 0(0) 2(11.1)
Erythromycin 18 9(50) 9(50) 0(0)
Ampicillin 18 2(11.1) 1(5.6) 15(83.3)
Flucloxacillin 18 3(16.7) 0(0) 15(83.3)
Cefuroxime 18 9(50) 1(5.6) 8(44.4)
Gentamicin 18 15(83.3) 0(0) 3(16.7)
Methicillin 18 12(66.7) 0(0) 6(33.3)
Vancomycin 18 15(83.3) 0(0) 3(16.7)
Penicillin 18 0(0) 0(0) 18(100)
Other gram positive Tetracycline 13 6(46.2) 0(0) 7(53.8)
Cotrimoxazole 13 7(53.8) 0(0) 6(46.2)
Erythromycin 13 6(46.2) 3(23.1) 4(30.7)
Ampicillin 13 3(23.1) 1(7.7) 9(69.2)
Flucloxacillin 13 2(15.4) 0(0) 11(84.6)
Cefuroxime 13 6(46.2) 0(0) 7(53.8)
Gentamicin 13 11(84.6) 0(0) 2(15.3)
Penicillin 13 2(15.4) 0(0) 11(84.6)
Other gram negatives Gentamicin 45 37(82.2) 1(2.2) 7(15.6)
Ceftriaxone 17 10(58.8) 2(11.8) 5(29.4)
Cefotaxime 39 16(41.0) 4(10.3) 19(48.7)
Ampicillin 45 0(0) 1(2.2) 44(97.8)
Tetracycline 45 1(2.3) 0(0) 44(97.8)
Cotrimoxazole 45 7(15.6) 0(0) 38(84.4)
Cefuroxime 45 5(11.1) 10(22.2) 30(66.7)
Chloramphenicol 39 6(15.4) 2(5.1) 31(79.5)
doi:10.1371/journal.pntd.0002191.t003
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acknowledge that true VRSA is rare, and that the occurrence of
apparent VRSA is being followed up through referral of isolates to
an international reference laboratory.
Postoperative infections of wounds represent the commonest
surgical complication causing substantial increases in the duration
and costs of hospital stays [40]. Our pilot study involving BU
patients at different time points of SR8 treatment indicates that
secondary bacterial infection may be a prominent cause for delays
in wound healing and skin grafting failures. These findings call for
an optimization of BU wound management and hygiene
procedures to better control secondary infections. Also the choice
of treatment of secondary infections with locally available
antimicrobial agents requires a better understanding of the
infecting flora and of drug susceptibility patterns. Our study did
not follow the same patients from beginning of treatment till they
were healed and this has limited the ability to determine causes
and consequences of wound infection. More studies are required
to ascertain the impact and source of wound infection in SR8
treatment of BU and to support development of guidelines for
wound care in BU case management. In addition to wounds we
also analyzed bandages that have been washed by the patients
themselves to be re-used for wound dressing. From these bandages
we isolated potential wound pathogens including S. aureus, P.
aeruginosa, Flavibacterium oryzihabitans, Enterobacter agglomerans and
Enterobacter cloaca; thus the bacteria profile of the wound samples
was comparable to that of the bandages. These findings indicate
that the recycling of bandages may not be a good practice as it
may be one of the sources of wound infection. We recommend
that if for economical reasons bandages need to be recycled, they
must be washed well with an appropriate disinfectant.
Supporting Information
Figure S1 Direct smear examination of infected wounds
and Kirby-Bauer plate of a VRSA isolate. Exudates from
infected wounds were smeared directly over clean microscopic
slides. The slides were then stained by the Gram procedure and
viewed under oil immersion. While the exudate on Plate A is
derived from the lesion of the patient whose biopsy was analyzed
by histopathology before SR8 (Figure 1), the smears on plate B
and C were taken from cases after SR8 treatment. Plate D depicts
the drug susceptibility result of two S. aureus isolates. While one
strain is both methicillin and vancomycin resistant, the other is
methicillin resistant, but vancomycin susceptible.
(TIF)
Table S1 Samples taken and types of analysis conduct-
ed at various stages of treatment.
(DOC)
Table 4. Microbiological analysis of recycled bandages.
CASE
BACTERIAL LOAD
(CFU/g) ORGANISM ISOLATED ANTIBIOTIC SUSCEPTIBILITY
SENSITIVE INTERMEDIATE RESISTANT
CASE 1 9.56107 Enterobacter agglomerans CTX, TET, AMK, COT,
GEN, CHL
AMP, CRX
CASE 2 5.36107 Staphylococcus warneri COT, CRX, GEN ERY PEN, AMP, FLX, TET
CASE 3 5.56104 Staphylase negative Staphylococcus TET, COT, CRX, GEN ERY PEN, AMP, FLX
CASE 4 1.106106 N/D
CASE 5 3.26108 Staphylase positive Staphylococcus TET, COT, CRX, GEN PEN, AMP, FLX, TET
CASE 6 1.226105 N/D
CASE 7 1.676106 Flavibacterium oryzihabitans TET, AMK, GEN CRX, CTX AMP, COT, CHL
CASE 8 8.66105 Staphylase negative Staphylococcus GEN PEN, AMP, FLX, ERY,
TET, COT, CRX
Pseudomonas sp CTX, TET, COT, CHL AMP, CRX,
AMK,GEN
CASE 9 4.16103 Staphylase negative Staphylococcus TET, COT, CRX, GEN PEN, AMP, FLX, ERY
CASE 10 3.36105 Staphylase negative Staphylococcus GEN CRX PEN, AMP, FLX, ERY,
TET, COT
CASE 11 3.16103 Staphylase negative Staphylococcus TET, GEN CRX PEN, AMP, FLX, ERY,
COT
CASE 12 6.36104 Staphylase negative Staphylococcus TET, COT, CRX, GEN ERY PEN, AMP, FLX
CASE 13 1.656105 Enterobacter cloacae CTX, TET, COT, GEN, CHL AMK AMP, CRX
CASE 14A 4.46104 Staphylase positive Staphylococcus TET, GEN CRX PEN, AMP, FLX, ERY,
COT
CASE 14B 5.36103 Staphylase negative Staphylococcus GEN PEN, AMP, FLX, ERY,
TET, COT, CRX
CASE 15A NEGLIGIBLE Staphylase negative Staphylococcus GEN ERY, CRX PEN, AMP, FLX, TET,
COT
CASE 15B NEGLIGIBLE N/D
AMP=Ampicillin, CXM=Cefixime, CXC= Cloxacillin, COT = Cotrimoxazole, ERY = Erythromycin, GEN=Gentamicin, TET = Tetracycline, PEN = Penicillin, CRX =Cefuroxime,
CHL = Chloramphenicol, CTR = Ceftriaxone, CTX = Cefotaxime.
doi:10.1371/journal.pntd.0002191.t004
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